Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
In the pharmacy business, unit fees increased as the company made progress in obtaining dispensing technical fees, while the number of prescriptions processed declined due to longer prescription periods and other factors. The BPO business recorded higher revenue and profit due to an increase in the number of MR dispatches, expansion of contracted services for occupational physicians and occupational health nurses, and the acquisition of large-scale projects. The pharmaceutical business recorded substantial increases in revenue and profit due to the contribution of 2 active ingredients and 5 products launched in the previous fiscal year, as well as lower costs for existing products.
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥73,912 million (YoY +3.0%) |
| Operating profit | ¥6,183 million (YoY +72.1%) |
| Ordinary income | ¥6,159 million (YoY +69.5%) |
| Profit attributable to owners of the parent | ¥3,002 million (YoY +61.7%) |
| Net income per share | ¥79.90 |
| Equity ratio | End of the current fiscal period 36.3 / End of previous period 36.3 |
| Total assets | ¥163,686 million |
| Net assets | ¥61,535 million |
| Full-year earnings forecast | Net Sales ¥315,000 million (YoY +8.3%) / Operating profit ¥16,500 million (YoY +11.4%) / Ordinary income ¥16,500 million (YoY +10.9%) / Net income ¥7,800 million (YoY +5.3%) |
| Revision to Earnings Forecast | No |
| Annual Dividend Forecast | ¥50 → ¥54 |
| Segment revenue | Pharmacy business ¥43,694 million (YoY +2.0%), BPO Services ¥3,836 million (YoY +10.1%), Pharmaceutical Business ¥26,381 million (YoY +3.8%) |
| Segment profit | Pharmacy business ¥1,669 million (YoY -4.7%), BPO Services ¥649 million (YoY +31.5%), Pharmaceutical Business ¥4,940 million (YoY +113.3%) |
| Depreciation and amortization | ¥1,519 million |
| Breakdown of extraordinary income (loss) | Gain on sale of non-current assets ¥0 million, Loss on Disposal of Fixed Assets ¥9 million, Other ¥2 million |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies (company name: —) / Excluded 0 companies (company name: —) |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 38,902,785 |
| Treasury Shares at Period-End | 1,325,219 |
| Factors Behind Changes in Business Performance | In the pharmacy business, unit fees increased as the company made progress in obtaining dispensing technical fees, while the number of prescriptions processed declined due to longer prescription periods and other factors. The BPO business recorded higher revenue and profit due to an increase in the number of MR dispatches, expansion of contracted services for occupational physicians and occupational health nurses, and the acquisition of large-scale projects. The pharmaceutical business recorded substantial increases in revenue and profit due to the contribution of 2 active ingredients and 5 products launched in the previous fiscal year, as well as lower costs for existing products. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the pharmacy business, unit fees increased as the company made progress in obtaining dispensing technical fees. In the BPO business, revenue and profit benefited from an increase in the number of MR dispatches, expansion of contracted services for occupational physicians and occupational health nurses, and the acquisition of large-scale projects. In the pharmaceutical business, results benefited from the contribution of 2 active ingredients and 5 products launched in the previous fiscal year, as well as lower costs for existing products.